Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R
Laboratory of Immunology, Aichi Cancer Center Research Institute, Japan.
Cancer Res. 1993 Jan 1;53(1):1-4.
We evaluated the prognostic significance of p53 mutations and an allelic loss of chromosome 3p in 71 patients with non-small cell lung cancer who underwent potentially curative resection. p53 mutations were detected in 35 cases (49%), while 3p deletions were observed in 34 of 70 informative cases (49%). The presence of the p53 mutation was associated with a shortened survival in all patients (P = 0.014 by log rank test), including those in early stages of the disease (stage I or II, n = 48) (P = 0.016 by log rank test). Multivariate analysis by the Cox proportional hazards model also revealed that p53 mutation was an independent yet unfavorable prognostic factor (P = 0.013). Patients with 3p deletion tended to have a poorer prognosis, but not to a statistically significant extent.
我们评估了71例行根治性切除的非小细胞肺癌患者中p53突变和3号染色体短臂等位基因缺失的预后意义。35例(49%)检测到p53突变,70例信息完整的病例中有34例(49%)观察到3p缺失。p53突变的存在与所有患者的生存期缩短相关(对数秩检验P=0.014),包括疾病早期(Ⅰ期或Ⅱ期,n=48)的患者(对数秩检验P=0.016)。Cox比例风险模型的多因素分析还显示,p53突变是一个独立的不良预后因素(P=0.013)。3p缺失的患者预后往往较差,但未达到统计学显著程度。